{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T15:21:00Z","timestamp":1725636060593},"publisher-location":"Berlin, Heidelberg","reference-count":17,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783540509844"},{"type":"electronic","value":"9783642746437"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1990]]},"DOI":"10.1007\/978-3-642-74643-7_65","type":"book-chapter","created":{"date-parts":[[2011,11,21]],"date-time":"2011-11-21T01:03:37Z","timestamp":1321837417000},"page":"342-345","source":"Crossref","is-referenced-by-count":2,"title":["Oral Idarubicin in Elderly Acute Leukemia and Refractory Anemia with Excess of Blasts"],"prefix":"10.1007","author":[{"given":"A.","family":"Berrebi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Polliack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"65_CR1","first-page":"829","volume":"60","author":"F Arcamone","year":"1976","unstructured":"Arcamone F, Bernardi L, Giordino P, Dimarco A, Casazza AM, Pratesi G (1976) Synthesis and antitumor activity of 4-demetoxy-344 daunorubicin, 4-demethy-7-9-diepidaunorubicin and their anomers. Cancer Treat Rep 60: 829\u2013834","journal-title":"Cancer Treat Rep"},{"key":"65_CR2","first-page":"834","volume":"63","author":"AM Casazza","year":"1979","unstructured":"Casazza AM (1979) Experimental evaluation of anthracycline analogues. Cancer Treat Rep 63: 834\u2013844","journal-title":"Cancer Treat Rep"},{"key":"65_CR3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000401466","volume":"23","author":"A Marco Di","year":"1978","unstructured":"Di Marco A, Zunio F, Casazza AM (1978) Comparison of biochemical and biological methods in the evaluation of a new anthracycline. Antibiot Chemother 23: 12\u201320","journal-title":"Antibiot Chemother"},{"key":"65_CR4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/030089168006600503","volume":"66","author":"AM Casazza","year":"1980","unstructured":"Casazza AM, Pratresi G, Giuliani F, Di Marco A (1980) Antileukemic activity of 4- demethoxydaunorubicin in mice. Tumori 66: 549\u2013564","journal-title":"Tumori"},{"key":"65_CR5","first-page":"893","volume":"61","author":"F Marco Di","year":"1977","unstructured":"Di Marco F, Casazza AM, Pratresi G (1977) Antitumor activity of 4-demethoxydaunorubicin administered orally. Cancer Treat Rep 61: 893 - 894","journal-title":"Cancer Treat Rep"},{"key":"65_CR6","first-page":"16","volume":"20","author":"A Casazza","year":"1979","unstructured":"Casazza A, Berlozolli G, Pratresi G, Bellini O, Di Marco A (1979) Antileukemic activity and cardiac toxicity of 4-demethoxydaunorubicin. Proc Am Assoc Cancer Res 20: 16","journal-title":"Proc Am Assoc Cancer Res"},{"key":"65_CR7","first-page":"6096","volume":"43","author":"E Berman","year":"1983","unstructured":"Berman E, Wittes RE, Leyland-Jones B et al. (1983) Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 43: 6096\u20136101","journal-title":"Cancer Res"},{"key":"65_CR8","doi-asserted-by":"crossref","unstructured":"Kaplan S, Sessa C, Willems Y, Pacciarini MA, Tamassia V, Cavalli F (1984) Phase I trial of 4-demethoxydaunorubicin ( Idarubicin) with single oral doses. Invest New Drugs 2: 281\u2013286","DOI":"10.1007\/BF00175378"},{"key":"65_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/BF00264204","volume":"21","author":"NS Stuart","year":"1988","unstructured":"Stuart NS, Cullen MH, Blackledge GRP, Priestman TJ, Spooner D (1988) Phase II study of oral 4-demethoxydaunorubicin in advanced breast cancer. Cancer Chemother Pharmacol 21: 351\u2013354","journal-title":"Cancer Chemother Pharmacol"},{"key":"65_CR10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennet","year":"1982","unstructured":"Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1982) The French-American-British (FAB) cooperative group. Proposals for the classification of the myelodysplasia syndromes. Br J Haematol 51: 189\u2013199","journal-title":"Br J Haematol"},{"key":"65_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2141.1983.tb02852.x","volume":"55","author":"DJ Weisdorf","year":"1983","unstructured":"Weisdorf DJ, Oken MM, Johnson AJ, Rydell RE (1983) Chronic myelodysplasia syndrome: short survival with or without evolution to acute leukaemia. Br J Haematol 55: 691\u2013700","journal-title":"Br J Haematol"},{"key":"65_CR12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2141.1977.tb08808.x","volume":"37","author":"Y Najean","year":"1977","unstructured":"Najean Y, Pecking A (1977) Refractory anaemia with excess of myeloblasts in the bone marrow: a clinical trial of androgens in 90 patients. Br J Haematol 37: 25\u201333","journal-title":"Br J Haematol"},{"key":"65_CR13","first-page":"981","volume":"67","author":"EJ Gold","year":"1983","unstructured":"Gold EJ, Mertelsmann RH, Intri LM, Gee T, Arlin Z, Kempin S, Clarkson B, Moore MAS (1983) Phase I clinical trial of 13-c\/s-retinoic acid in myelodysplasia syndromes. Cancer Treat Rep 67: 981\u2013986","journal-title":"Cancer Treat Rep"},{"key":"65_CR14","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1002\/1097-0142(197912)44:6<1976::AID-CNCR2820440603>3.0.CO;2-#","volume":"44","author":"Y Najean","year":"1979","unstructured":"Najean Y, Pecking A (1979) Refractory anaemia with excess of blast cells: prognostic factors and effect of treatment with androgens or cytosine arabinoside. Cancer 44: 1976\u20131982","journal-title":"Cancer"},{"key":"65_CR15","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJM198312293092602","volume":"309","author":"JS Wisch","year":"1983","unstructured":"Wisch JS, Griffin JD, Kufe DW (1983) Response of preleukaemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med 309: 1599\u20131602","journal-title":"N Engl J Med"},{"key":"65_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1600-0609.1987.tb01416.x","volume":"38","author":"M Shtalrid","year":"1987","unstructured":"Shtalrid M, Lotem S, Sachs L, Berrebi A (1987) Review of clinical and haematological response to low-dose ARA-C in acute myeloid leukemia. Eur J Haematol 38: 3\u201311","journal-title":"Eur J Haematol"},{"key":"65_CR17","first-page":"247","volume-title":"12th Meeting of the International Society of Hematology, Milano","author":"R Bock De","year":"1988","unstructured":"De Bock R, Van Hove W, Van Hoof A, Zachee IP, Mathigs R, Ferrant A, Lobell JP, Peetersmans ME (1988) Oral idarubicin for RAEB, RAEB-T, AL post MDS: a phase II open study. In: 12th Meeting of the International Society of Hematology, Milano 1988, p 247"}],"container-title":["Haematology and Blood Transfusion \/ H\u00e4matologie und Bluttransfusion","Acute Leukemias II"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-74643-7_65.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T21:29:23Z","timestamp":1606253363000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-74643-7_65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990]]},"ISBN":["9783540509844","9783642746437"],"references-count":17,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-74643-7_65","relation":{},"ISSN":["0440-0607"],"issn-type":[{"type":"print","value":"0440-0607"}],"subject":[],"published":{"date-parts":[[1990]]}}}